CN105163584B - 用于治疗癌症的化合物 - Google Patents

用于治疗癌症的化合物 Download PDF

Info

Publication number
CN105163584B
CN105163584B CN201480025267.4A CN201480025267A CN105163584B CN 105163584 B CN105163584 B CN 105163584B CN 201480025267 A CN201480025267 A CN 201480025267A CN 105163584 B CN105163584 B CN 105163584B
Authority
CN
China
Prior art keywords
cancer
another embodiment
compound
cell
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480025267.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105163584A (zh
Inventor
J·王
陈建军
D·D.·米勒
李伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Priority to CN201811371741.5A priority Critical patent/CN109568312A/zh
Publication of CN105163584A publication Critical patent/CN105163584A/zh
Application granted granted Critical
Publication of CN105163584B publication Critical patent/CN105163584B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480025267.4A 2013-03-05 2014-03-05 用于治疗癌症的化合物 Active CN105163584B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811371741.5A CN109568312A (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772885P 2013-03-05 2013-03-05
US61/772,885 2013-03-05
PCT/US2014/020858 WO2014138279A1 (en) 2013-03-05 2014-03-05 Compounds for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811371741.5A Division CN109568312A (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物

Publications (2)

Publication Number Publication Date
CN105163584A CN105163584A (zh) 2015-12-16
CN105163584B true CN105163584B (zh) 2019-06-04

Family

ID=51491914

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480025267.4A Active CN105163584B (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物
CN201811371741.5A Pending CN109568312A (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811371741.5A Pending CN109568312A (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物

Country Status (11)

Country Link
US (2) US10022356B2 (https=)
EP (1) EP2964028A4 (https=)
JP (2) JP6835472B2 (https=)
KR (1) KR102246652B1 (https=)
CN (2) CN105163584B (https=)
AU (2) AU2014225761B2 (https=)
CA (1) CA2904338C (https=)
IL (1) IL241232B (https=)
MX (2) MX375059B (https=)
RU (1) RU2708247C2 (https=)
WO (1) WO2014138279A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009330686B2 (en) * 2008-06-16 2014-07-03 The Ohio State University Research Foundation Compounds for the treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
ES2815374T3 (es) 2014-05-06 2021-03-29 Oncternal Therapeutics Inc Compuestos para el tratamiento del cáncer
CN104434924B (zh) * 2014-11-10 2016-09-14 暨南大学 曲美替尼在制备逆转肿瘤多药耐药性药物中的应用
ES2827024T3 (es) * 2014-12-23 2021-05-19 Dot Therapeutics 1 Inc Combinación de inhibidores de Raf y de taxanos
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
DK3302478T3 (da) * 2015-06-05 2022-02-14 The Board Of Trustees Of The Univ Of Illionis Pac-1 kombinations behandling
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
WO2017007495A1 (en) * 2015-07-09 2017-01-12 The Jackson Laboratory Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor
ES2992827T3 (en) * 2015-08-06 2024-12-18 Wistar Inst Combination therapies targeting mitochondrial biogenesis for cancer therapy
JP6987084B2 (ja) 2016-03-16 2021-12-22 ディセルナ ファーマシューティカルズ インコーポレイテッド β−カテニン関連疾患又は障害の治療のための組成物及び方法
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3594357A4 (en) * 2017-03-10 2020-03-11 Konica Minolta, Inc. METHOD FOR ESTIMATING THERAPEUTIC EFFECTIVENESS
CN111655228B (zh) 2017-05-03 2024-02-09 听治疗有限责任公司 预防和治疗听力损失的组合物和方法
SG11202004384YA (en) 2017-11-17 2020-06-29 Univ Illinois Cancer therapy by degrading dual mek signaling
CN108218855A (zh) * 2018-03-12 2018-06-29 桑文军 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用
JP2021523915A (ja) * 2018-05-15 2021-09-09 ユニバーシティ オブ テネシー リサーチ ファウンデーション 膵臓癌の治療のための化合物
UA125551C2 (uk) * 2018-05-15 2022-04-13 Юніверсіті Оф Теннессі Рісерч Фаундейшн Спосіб лікування тричі негативного раку молочної залози або раку яєчника
KR20210084442A (ko) 2018-10-05 2021-07-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 포도막 흑색종 치료를 위한 병용 요법
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
CN115279376A (zh) * 2020-01-31 2022-11-01 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合疗法
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
US20230355581A1 (en) * 2020-07-02 2023-11-09 The Board of Regents of the Unversity of Texas System Methods of treatment for melanoma
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects
WO2022131667A1 (ko) * 2020-12-18 2022-06-23 경희대학교 산학협력단 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
CN115504964A (zh) * 2022-04-12 2022-12-23 海创药业股份有限公司 氘代杂环酮类化合物及其用途
CN117143081B (zh) * 2022-05-24 2025-08-01 赣南医科大学 一种Sabizabulin的制备方法
WO2024036114A2 (en) * 2022-08-08 2024-02-15 The Regents Of The University Of California Combination therapy including cox-2 inhibitor for the treatment of cancer
WO2024186641A1 (en) * 2023-03-03 2024-09-12 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
US20250032788A1 (en) * 2023-06-30 2025-01-30 Novocure Gmbh Compositions and methods for treating with a combination of alternating electric fields and dna-dependent protein kinase inhibitors
CN119409641A (zh) * 2024-11-05 2025-02-11 杭州电子科技大学 一种磺酰基衍生物和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102655753A (zh) * 2009-10-16 2012-09-05 葛兰素史密丝克莱恩有限责任公司 组合药
CN102883607A (zh) * 2010-03-01 2013-01-16 Gtx公司 用于治疗癌的化合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
DK0934937T3 (da) 1990-11-30 2002-04-02 Otsuka Pharma Co Ltd Azolderivater som superoxidradikalinhibitor
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
JP2550915B2 (ja) 1994-06-21 1996-11-06 日本電気株式会社 印刷配線板の表面保護剤および表面保護膜の形成方法
CA2433018A1 (en) 2000-12-21 2002-06-27 Joel C. Barrish Thiazolyl inhibitors of tec family tyrosine kinases
CA2461363A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
AU2002352706A1 (en) 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
JP2006518738A (ja) 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
JP4726235B2 (ja) 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癌の処置のためのチェックポイントキナーゼｃｄｓ１（ｃｈｋ２）インヒビターとしての２−フェニル−ベンズイミダゾールおよび２−フェニル−イミダゾ−‘４，５！−ピリジン誘導体
US20040242673A1 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US7307093B2 (en) 2003-11-18 2007-12-11 The University Of Tennessee Research Foundation Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof
RU2006124843A (ru) 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
JP2007527917A (ja) 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
EP2298291A3 (en) 2004-06-18 2011-08-03 Agennix USA Inc. Kinase inhibitors for treating cancers
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
CN102206216B (zh) * 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
WO2007132867A1 (ja) * 2006-05-15 2007-11-22 Takeda Pharmaceutical Company Limited 癌の予防及び治療剤
US7464893B2 (en) * 2006-06-30 2008-12-16 Per Spjut Method of using a cord holder
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
AU2009330686B2 (en) 2008-06-16 2014-07-03 The Ohio State University Research Foundation Compounds for the treatment of cancer
US8426418B2 (en) * 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
US9348332B2 (en) 2011-03-29 2016-05-24 Mitsubishi Electric Corporation Abnormality diagnosis device and abnormality diagnosis system for servo control device
KR102021157B1 (ko) * 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
SI2694510T1 (sl) * 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
JP6835472B2 (ja) * 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102655753A (zh) * 2009-10-16 2012-09-05 葛兰素史密丝克莱恩有限责任公司 组合药
CN102883607A (zh) * 2010-03-01 2013-01-16 Gtx公司 用于治疗癌的化合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Anna Tesei et al..Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.《J. Cell. Mol. Med.》.2011,第15卷(第2期),316-326. *
Jianjun Chen et al..Discovery of Novel 2‑Aryl-4-benzoyl-imidazole (ABI-III) Analogues Targeting Tubulin Polymerization As Antiproliferative Agents.《Journal of Medicinal Chemistry》.2012,第55卷(第16期),7285-7289. *
Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models;Anna Tesei et al.;《J. Cell. Mol. Med.》;20110201;第15卷(第2期);316-326 *
Nikolas K. Haass et al..TheMitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase InhibitorAZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel.《Clin Cancer Res》.2008,第14卷(第1期),230-239. *
Sapna P. Patel, MD et al..Clinical Responses to Selumetinib (AZD6244;ARRY-142886)-Based Combination Therapy Stratified by Gene Mutations in Patients With Metastatic Melanoma.《Cancer》.2012,第119卷(第4期),799-805. *
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression;Lucy Lee et al.;《J Clin Pharmacol》;20101231(第50期);1397-1405 *
TheMitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase InhibitorAZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel;Nikolas K. Haass et al.;《Clin Cancer Res》;20080101;第14卷(第1期);230-239 *
Therapeutic options in cutaneous melanoma: latest developments;245-251;《Therapeutic Advances in Medical Oncology》;20110901;第3卷(第5期);245-251 *

Also Published As

Publication number Publication date
MX375059B (es) 2025-03-06
EP2964028A4 (en) 2017-06-07
JP6835472B2 (ja) 2021-02-24
WO2014138279A1 (en) 2014-09-12
RU2708247C2 (ru) 2019-12-05
AU2014225761A1 (en) 2015-10-08
RU2015142102A3 (https=) 2018-03-13
EP2964028A1 (en) 2016-01-13
KR102246652B1 (ko) 2021-04-29
MX2015011713A (es) 2016-05-09
IL241232A0 (en) 2015-11-30
CA2904338A1 (en) 2014-09-12
AU2014225761B2 (en) 2018-06-07
CA2904338C (en) 2022-07-05
MX2020009256A (es) 2020-10-28
AU2018226470B2 (en) 2019-11-28
US20180325872A1 (en) 2018-11-15
IL241232B (en) 2021-02-28
KR20150123328A (ko) 2015-11-03
CN105163584A (zh) 2015-12-16
CN109568312A (zh) 2019-04-05
US20160015688A1 (en) 2016-01-21
RU2015142102A (ru) 2017-04-07
JP2016510748A (ja) 2016-04-11
AU2018226470A1 (en) 2018-09-27
US10022356B2 (en) 2018-07-17
US10525037B2 (en) 2020-01-07
JP2019077727A (ja) 2019-05-23

Similar Documents

Publication Publication Date Title
CN105163584B (zh) 用于治疗癌症的化合物
CN110072528B (zh) 治疗肿瘤的药物组合物
CN109069504B (zh) 氨基噻唑化合物及其用途
JP6867295B2 (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
JP5662321B2 (ja) 骨髄腫の治療のための置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンの使用
TW202019407A (zh) Bcl-2抑制劑與MDM2抑制劑的組合產品及其在預防及/或治療疾病中的用途
JP2015536986A (ja) 併用療法
CN104436194B (zh) 具有协同增效作用的抗癌组合物
CN114867622A (zh) 涉及二芳基巨环化合物的组合疗法
TW202019409A (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用
US20180250261A1 (en) Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
CN101222850B (zh) 治疗对药物有抗性的癌症的方法
JP6239103B2 (ja) チロシンキナーゼ阻害活性を有する物質ならびにその調製方法および使用
AU2017235350B2 (en) Combination therapy for proliferative diseases
CN108473504B (zh) 新型二氢吡喃并嘧啶酮衍生物及其用途
CN120813358A (zh) 用于治疗肿瘤的药物组合物
JP2019014685A (ja) 抗がん剤
HK40005718A (en) Compounds for treatment of cancer
TWI594982B (zh) 低細胞毒性血管阻斷劑
JP2012087118A (ja) 抗腫瘍剤
KR20140105991A (ko) 7-에톡시아크리딘-3,9-디아민； 2-하이드록시프로판산 또는 디브로모하이드록시머큐리플루오레세인을 유효성분으로 포함하는 암 치료 또는 예방용 약학적 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant